Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAfore
2023-507772-50-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan, enzalutamide and abiraterone in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoint: Radiographic progression-free survival. Started Jun 2021; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetanenzalutamideabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-507772-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507772-50-00.